New D3 (PENTA-21) findings add reassurance about simplified HIV treatment for children
2026
New results from the D3 (PENTA-21) trial, sponsored by Fondazione Penta ETS, add to the evidence that dolutegravir-based treatment remains a strong option for children living with HIV,